ziftomenib
kura oncology
['aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'ziftomenib', '$kura', 'kura ']
$kura oncology presents late-breaking clinical data for menin inhibitor ziftomenib at #eha2023 orr 45%, ccr 40%, cr 35% in mpm1m aml (7/20), mdor 8.2mo, 30% gr3+traes, 20% diff syndrome (1 gr3 "manageable") slides 
Biotellytics / https://t.co/37itIfRolp = business intel service on listed European Bios / Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design)